


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**1. (Currently Amended)** A pharmaceutical composition comprising:

(a) an anticholinergic of formula 1



wherein X<sup>-</sup> is an anion with a single negative charge,

(b) a corticosteroid; and

(c) a betamimetic,

wherein each component (a), (b), and (c) ~~are~~ is optionally in the form of ~~solvates or hydrates~~ a solvate or hydrate thereof.

**2. (Original)** The pharmaceutical composition according to claim 1, further comprising a physiologically acceptable excipient.

**3. (Original)** The pharmaceutical composition according to claim 2, wherein the physiologically acceptable excipient is a monosaccharide, disaccharide, oligo- or polysaccharide, polyalcohol, salt, or mixture thereof.

4. **(Original)** The pharmaceutical composition according to claim 1, wherein:  
X<sup>-</sup> is selected from the group consisting of: chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, and p-toluenesulfonate.
5. **(Original)** The pharmaceutical composition according to claim 1, wherein:  
X<sup>-</sup> is selected from the group consisting of: chloride, bromide, methanesulfonate, and p-toluenesulfonate.
6. **(Original)** The pharmaceutical composition according to claim 1, wherein X<sup>-</sup> is bromide.
7. **(Original)** The pharmaceutical composition according to claim 1, wherein the corticosteroid is selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW215864, KSR592, ST-126, dexamethasone, and mixtures thereof.
8. **(Original)** The pharmaceutical composition according to claim 1, wherein the corticosteroid is selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, dexamethasone, and mixtures thereof.
9. **(Original)** The pharmaceutical composition according to claim 1, wherein the betamimetic is selected from bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulfoneterol, terbutaline, tolubuterol, 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{4-[3-(4-

methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino} ethanol, 5-hydroxy-8-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert-butylamino)ethanol, 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert-butylamino)ethanol, and mixtures thereof.

**10. (Original)** The pharmaceutical composition according to claim 1, wherein the betamimetic is selected from formoterol, salmeterol, 4-hydroxy-7-[2-{{2-{{3-(2-phenylethoxy)propyl}sulfonyl }ethyl]amino}ethyl]-2(3H)-benzothiazolone, 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-{{4-{{3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino} ethanol, and mixtures thereof.

**11. (Original)** The pharmaceutical composition according to one of claims 1 to 10, wherein the weight ratio of the anticholinergic in the form of its cation to the corticosteroid is in the range from 1:250 to 250:1.

**12. (Original)** The pharmaceutical composition according to one of claims 1 to 10, wherein the weight ratio of anticholinergic to the betamimetic is in the range from 1:300 to 30:1.

**13. (Original)** The pharmaceutical composition according to one of claims 1 to 10, wherein the total amount of the anticholinergic, the corticosteroid, and the betamimetic is 1 µg to 10000 µg.

**14. (Original)** The pharmaceutical composition according to claim 1, wherein the total amount of the anticholinergic, the corticosteroid, and the betamimetic is 10 µg to 2000 µg.

**15. (Original)** The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in a form suitable for inhalation.

**16. (Currently Amended)** The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is an inhalable powder, ~~propellant-containing aerosol composition~~, or a propellant-free inhalable solution or suspension.

**17. (Original)** The pharmaceutical composition according to one of claims 2 to 10, wherein the pharmaceutical composition is in a form suitable for inhalation.


**18. (Original)** The pharmaceutical composition according to one of claims 2 or 3, wherein the pharmaceutical composition is an inhalable powder and the physiologically acceptable excipient has a maximum average particle size of up to 250  $\mu\text{m}$ .

**19. (Original)** The pharmaceutical composition according to claim 18, wherein the physiologically acceptable excipient has a maximum average particle size of between 10  $\mu\text{m}$  and 150  $\mu\text{m}$ .

**20. (Original)** A capsule containing inhalable powder according to claim 18.

**21. (Original)** A pharmaceutical composition consisting essentially of:

(a) an anticholinergic of formula 1



wherein  $X^-$  is an anion with a single negative charge;

(b) a corticosteroid; and

(c) a betamimetic,

wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof.

**22. – 27. (Canceled)**